TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01370486
Drug: melatonin
Normalized name: Melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: melatonin cp 2 mg 1x/d for 1 month
Study: NCT01370486
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo cp 1x/d for 1 month
Study: NCT00642460
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: iv every 2 weeks for 12 weeks
Study: NCT00788593
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching to EUR-1008 (APT-1008) capsules orally daily for 4 days home treatment and 3 to 5 days hospital treatment in the baseline run-in phase, which will then be randomized to either high dose or low dose of EUR-1008 (APT-1008).
Study: NCT00766155
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given orally
Study: NCT02040311
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00642460
Drug: Non-steroidal anti-inflammatory drugs (NSAIDs)
Normalized name: Surpass Anti-Inflammatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: as prescribed
Study: NCT00642460
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: as prescribed
Study: NCT00642460
Drug: corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: orally, as prescribed
Study: NCT02340221
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching to taselisib was administered as per the schedule specified in the respective arm.
Study: NCT06451393
Drug: Neoadjuvant chemotherapy with radical tumor resection surgery
Normalized name: human breast tumor cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients were pathologically diagnosed as advanced gastric cancer, all receive neoadjuvant chemotherapy, after the completion of neoadjuvant chemotherapy, all patients receive radical tumor resection surgery (partial gastrectomy or total gastrectomy, as proper).
Study: NCT03256422
Drug: Treatment discontinuation
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: • Receiving tritherapy. Allowed treatment drugs are :~1. nucleoside analogs : tenofovir (TDF ou TAF), emtricitabine, abacavir, lamivudine~2. protease inhibitors : lopinavir/r, darunavir/r ou atazanavir/r~3. non nucleoside reverse transcriptase inhibitors : efavirenz, rilpivirine ou etravirine~4. integrase inhibitors : dolutegravir, elvitegravir/cobicistat ou raltegravir
Study: NCT02608710
Drug: RDEA3170 4.5 mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00103402
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00003598
Drug: tretinoin
Normalized name: Tretinoin
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00794482
Drug: NRL972
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 2 mg NRL972 administered intravenously. Total volume 5 mL.
Study: NCT02608710
Drug: RDEA3170 6 mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02608710
Drug: RDEA3170 12 mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04013113
Drug: Haemoperfusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three sessions of Hemoperfusion, 1 plasma volume/session will be done to the selected patients.~Hemoperfusion will be done through bile acids and ammonia filters to adsorb bile acids and ammonia respectively.~Group specific fresh frozen plasma will be transfused to the patient through a peripheral vein catheter to prevent hypotension if required.
Study: NCT04013113
Drug: Standard Medical Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard medical therapy only included as per requirement.nutritional therapy ( high calorie intake- 2400 Kcal/ day) Lactulose, bowel wash, albumin, terlipressin, antibiotics and anti-virals in hepatitis B reactivation will be continued and recorded.
Study: NCT02677259
Drug: 17-beta estradiol
Normalized name: 17-beta estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01733147
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 capsules a day of placebo (1200 mg of ethyl oleate 3 capsules a day) taken orally for six months; 2 capsules with breakfast and 1 capsule with their evening meal.
Study: NCT02213913
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT02213913
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01436565
Drug: SAR245408
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form:tablet~Route of administration: oral
Study: NCT03168321
Drug: IDP-123 Lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tazarotene 0.045% Lotion
Study: NCT02563821
Drug: sufentanil
Normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01088919
Drug: ASP1941
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral tablet
Study: NCT00683982
Drug: Probiotic mix preparation
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic preparation 1 gram twice a day for 5 days
Study: NCT01663727
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous repeating dose
Study: NCT00375492
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneous injection, volume equivalent to exenatide dose, twice a day
Study: NCT01449045
Drug: Community Case Management with artemether-lumefantrine (AL)
Normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Lumefantrine co-artemether (DB13085)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Malaria diagnosis with Rapid Diagnostic Test and treatment with AL if the test is positive
Study: NCT01790035
Drug: LGG
Normalized name: LGG
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01790035
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04891965
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each placebo capsule is identical in appearance, weight, and packaging to ART24 capsules, but will contain only the inactive excipients. Subjects will receive 1 capsule daily.
Study: NCT00004748
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03575871
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, administered as two tablets to be taken orally once daily for 12 weeks
Study: NCT02818387
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Remifentanil 0.125 mcg/kg/min infusion for 5 min before propofol administration.
Study: NCT01045993
Drug: marketed analgesic
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 x 200 mg ibuprofen tablets
Study: NCT01045993
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 x placebo tablets
Study: NCT03911921
Drug: RSYRT decoction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compound granules of traditional Chinese medicine
Study: NCT03911921
Drug: Astragalus membranaceus
Normalized name: Astragalus membranaceus
Approvals — FDA: no, EMA: no, PMDA: no
Description: One herb
Study: NCT00338052
Drug: Norethindrone 1 mg / ethinyl estradiol 20 mcg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00110006
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide IV over 30 minutes. Treatment repeats every 14-21 days for up to 4 courses in the absence of unacceptable toxicity.
Study: NCT00110006
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin IV over 5 minutes. Treatment repeats every 14-21 days for up to 4 courses in the absence of unacceptable toxicity.
Study: NCT03132194
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: topical gel
Study: NCT02296853
Drug: TAF
Normalized name: Altafed
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg tablet administered orally
Study: NCT01829113
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three loading doses of placebo will be administered intravenously (IV) during a 9 day period. Then placebo (IV) will be given weekly on Days 1, 8 and 15 of each 21 day cycle prior to the administration of pemetrexed (500mg/m\^2 IV) and carboplatin (AUC 6 IV) on Day 1 of each cycle for a maximum of four treatment cycles. Patients who respond to treatment or have stable disease will continue to receive placebo (IV) plus 500mg/m2 IV pemetrexed weekly until toxicity or disease progression.
Study: NCT01095679
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Breaking tablets of 10 mg of placebo. Dosage and frequency : 5 mg 3 times a day for 3 days, then 10 mg 3 times a day for 3 days, then 15 mg 3 times a day for 3 days, then 20 mg 3 times a day for 3-5 days, then 15 mg 3 times a day for 1 day, then 10 mg 3 times a day for one day, then 5 mg 3 times a day for one day.
Study: NCT01882920
Drug: Goal Directed Intravenous Restrictive Fluid Therapy
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basal infusion of crystalloids (normal saline,Ringer's lactate,Ringer's solution) at 4 ml/kg/h and boluses of colloids (HES 130/0.4 ) for values of cardiac index (CI) \<2.5 l/min/m2, stroke volume index (SVI) \< 35 SVI ml/m2 and stroke volume variation (SVV)\> 15%. In the case of CI \<2.5 l/min/m2 and SVI \<35 ml/m2 with SVV \< 15%, an infusion with dopamine was initiated.
Study: NCT00072072
Drug: celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01338987
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide: 60 mg/kg intravenous (IV) on days -4 and -3 (for Adults \> 22 years) or Cyclophosphamide: cyclophosphamide 50 mg/kg IV, Days -5, -4, -3, -2. (For Pediatric \</= 22 years)
Study: NCT01338987
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate:10 mg/m(2) intravenous (IV) on day +1, and 5 mg/m(2) IV Days + 3, 6, 11
Study: NCT00728780
Drug: ABT-143
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: once
Study: NCT00728780
Drug: ABT-335 and rosuvastatin
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: once
Study: NCT00649727
Drug: Ditropan XL® Tablets 10 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2x10mg, single dose fed
Study: NCT02971982
Drug: Velcade/Dexamethasone/cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Velcade:1.3mg/m2,Dexamethasone 10mg q12h,cyclophosphamide 750mg
Study: NCT00671073
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, oral administration, once daily for 12 weeks
Study: NCT03697330
Drug: Ringer lactate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomization will be done using computer generated table of random numbers in a 1:1 ratio and will be conducted using sequentially numbered, opaque and sealed envelope. The trial will be planned that neither the doctors (investigators) nor the patients will be aware of the group allocation and amount of fluid received. Intraoperative and postoperative data collections will be achieved by the same blinded anesthiologist.~Patients will be randomly allocated into two groups:~Group L: 40 patients who will be subjected to ''liberal approach of intraoperative 18-20 ml/kg/h of Ringer's lactate starting from conduction of spinal anesthesia.~Group R: 40 patients who will be subjected to ''restrictive approach of intraoperative 4-6 ml/kg/h of Ringer's lactate starting from conduction of spinal anesthesia.~Blood loss will be replaced if more than 500 ml in a ratio of 3 ml crystalloid: 1 ml blood.
Study: NCT00110344
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cycle 1. Patients are randomized in a double-blind fashion to receive either Nexavar (see above) or matching placebo (this arm) for 14 days. Dose range will be depending on hematologic and other toxicity between 400mg (2 tablets of 200mg) orally twice bid and 400mg orally every 2 days. Cycle 2 and 3: see above (no placebo application)
Study: NCT00937651
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01770431
Drug: Huaier Granule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Huaier Granule is a traditional Chinese medicine, 20g / time, 3 times/day,Po.
Study: NCT00705692
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02328950
Drug: Fludarabine and Cytarabine followed by IV busulfan and cyclophosphamide
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludarabine (F) 30 mg/m²/day for 5 days (day -12 to day-8) Cytarabine (A) 2g/m²/day for 5 days (day -12 to day-8) Bulsufan (Bu) 0.8mg/kg/day for 3 days (day -7 to day-5) Cyclophosphamide(Cy) 1.8g/m²/day for 3 days (day -4 to day-3)
Study: NCT02408328
Drug: Caffeine citrate
Normalized name: Caffeine Citrate
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Loading dose and continues use of caffeine until 44 weeks postmenstrual age
Study: NCT01843348
Drug: Enteric Coated Mycophenolate Sodium (EC-MPS)
Normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablets: 180 mg or 360 mg. Dosing: duration of study 360 mg bid and no less than 360 mg daily dose
Study: NCT01843348
Drug: Corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: A minimum dose of 5 mg prednisolon or equivalent
Study: NCT02234206
Drug: Chandrakanthi Choornam (CKC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12gm in milk - OD dose; Oral route; 3 Months ( 90days) - duration~Preparation from approved sastric book as per drugs \& cosmetic act 1940
Study: NCT03994549
Drug: Dual GLP-1/GLP-2 Receptor agonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eight ascending doses of ZP7570
Study: NCT03465436
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered for lasmiditan or moxifloxacin
Study: NCT03347513
Drug: triple attack therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: eradication of H-pylori using triple attack therapy.
Study: NCT03347513
Drug: Ferrous(II)-glycine-sulphate complex 567.7 mg capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron therapy will be given to both groups twice daily for one month.
Study: NCT06490003
Drug: Fluoro Uracil
Normalized name: Fluoro Uracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Esophageal cancer chemotherapy（First line treatment)
Study: NCT01933464
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03832738
Drug: Placebo Tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets matching in appearance to the active drug tablets
Study: NCT04176588
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug:placebo Tablet
Study: NCT00002714
Drug: Stanford V regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00002714
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03580291
Drug: Placebo of Mycophenolate Mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The group receive placebo of oral mycophenolate mofetil.
Study: NCT00925301
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral capsule QOD
Study: NCT02046668
Drug: spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: spironolactone 25mg daily for 12 weeks
Study: NCT04334629
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lipid ibuprofen 200 mg
Study: NCT04465539
Drug: Hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hydrocortisone dose is 200-300 mg /day intravenously
Study: NCT00603291
Drug: Matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo tablet each morning and evening for a duration of 52 weeks.
Study: NCT03326674
Drug: Tesetaxel and Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tesetaxel plus reduced dose of Capecitabine
Study: NCT03326674
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine alone at approved dose
Study: NCT00293202
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hemodialysis patients will receive Saline by subcutaneous injection twice a week
Study: NCT04465539
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: received the standard ALP treatment according to TUPTC protocol as follows: patient resuscitation, care of airway, breathing and circulation, gastric decontamination with 2 ampoules sodium bicarbonate (each ampoule 25 ml containing 2.1 gm sodium bicarbonate) followed by activated charcoal in dose of 1 g/Kg orally, adequate hydration, normal saline administration (0.9% Sodium Chloride IV), vasopressors IV infusions, inhalation of 100% oxygen, ranitidine IV, magnesium sulfate IV infusion and other supportive treatment.
Study: NCT01450839
Drug: E2022
Normalized name: LARYNGEAL PROSTHESIS,BLOM-SINGER BE2022
Approvals — FDA: no, EMA: no, PMDA: no
Description: The treatment period consists of 2 periods, Period I and Period II. In Period I, one 5 mg E2020 tablet will be administered in a single dose. In Period II, the tape containing 16 mg E2022 (which corresponds to one 5 mg E2020 tablet) will be applied repeatedly for 17 days. A washout period of at least 8 days will be allowed between the day of single dose administration in Period I and the first day of repeated application in Period II. A post-treatment examination will be performed at least 21 days after the last removal of the investigational product in Period II.
Study: NCT01450839
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo tablets and tape
Study: NCT01288469
Drug: Placebo (for alirocumab)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One SC injection in the abdomen only.
Study: NCT01288469
Drug: Placebo (for atorvastatin)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One over-encapsulated tablet of placebo for atorvastatin orally once daily in the evening with dinner.
Study: NCT00331071
Drug: Ortho Evra transdermal patch containing 6 mg NGMN/0.75 mg EE
Approvals — FDA: no, EMA: no, PMDA: no
Description: worn for 1 week and replaced for 3 consecutive weeks
Study: NCT04715997
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline
Study: NCT00408564
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01763749
Drug: Closone
Normalized name: erythromycin estolate Oral Capsule [Ilosone]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Closone 75mg/100mg, 4weeks, PO
Study: NCT01763749
Drug: Plavix with Astrix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plavix 75mg with Astrix 100mg, 4weeks, PO
Study: NCT01060930
Drug: Intravenous infusion of L-NMMA and Nor-epinephrine
Normalized name: L-NMMA
DrugBank: Tilarginine (DB11815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of 3mg/kg L-NMMA (L-NG-monomethyl arginine; NO synthase inhibitor) and nor-epinephrine at 50 ng/kg/min. Each infusion to run over 15 mins and separated by 45 min to allow return to baseline. Drugs infused in a randomised order. During the study, blood pressure will be measured invasively using an intra-arterial radial artery cannula, central arterial stiffness measured using peripheral arterial tonometry and cardiac output using thoracic bioimpedance.
Study: NCT01674413
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 syringe of placebo SC q 2 weeks, with additional placebo loading of 3 syringes/1 syringe at Weeks 0/2, 12/14, 24/26, and 36/38 Weeks.
Study: NCT04254835
Drug: Cervitec F, Ivoclar Vivadent - Schaan Liechtenstein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoride varnish containing Chlorhexidine and Cetylpyridinium Chloride
Study: NCT04254835
Drug: Fluor Protector, Ivoclar Vivadent - Schaan Liechtenstein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional Fluoride varnish
Study: NCT01861236
Drug: Firmagon® (degarelix)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly subcutaneous injections
Study: NCT00560937
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (similar to active comparator) 50 mg BID x 2 weeks, Placebo (similar to active comparator) 150 mg BID x 2 weeks, Placebo (similar to active comparator) 250 mg BID x 4 weeks
Study: NCT02243293
Drug: ABT-493
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet
Study: NCT02243293
Drug: ABT-530
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet
Study: NCT02243293
Drug: ABT-493/ABT-530
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet; ABT-493 co-formulated ABT-530
Study: NCT02736682
Drug: Single dose antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose arm receive 2g of IV Ceftriaxone and 500 mgs ofIntra venous Metronidazole given to the mothers 30-60 minutes pre operative.
Study: NCT02736682
Drug: Multiple dose antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple dose arm receive 1 g of IV Cetriaxone plus 500 mgs during surgery and there after IV ceftriaxone once a day for 3 days and IV Metronidazole 500mgs during surgery and there after every 8 hours for 3 days.
Study: NCT00191789
Drug: doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 60 mg/m\^2, IV, every 21 days x 4 cycles (1-4)
Study: NCT02287129
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 625 mg/m2